Cipla receives 12 observations from USFDA inspection of its Goa facility
Cipla announced that the United States Food and Drug Administration (USFDA) conducted a cGMP inspection at its Goa manufacturing facility from 16-27 September 2019.
The inspection ended with 12 observations, none of which are related to data integrity. The Company will respond to the agency within the stipulated timeline.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Sep 28 2019 | 2:04 PM IST